Cerecor Inc. is a clinical-stage biopharmaceutical company focused on developing innovative drugs to make a difference in the lives of patients afflicted by neurological and psychiatric diseases. By applying our extensive knowledge and experience of neurological and psychiatric diseases and medications to treat them (“neuro-psychiatric drugs”), we have developed a systematic process to identify and advance compounds for underserved segments of common diseases and design clinical trials with the latest technologies to improve the signal-to-noise ratio and likelihood of trial success. Our process includes seeking candidates for which human proof-of-concept has been demonstrated for the compound or target and biomarkers have been identified to guide development. Learn More


March 20, 2015

Cerecor Provides Update on CERC-301 Development in Major Depressive Disorder

Read More

February 20, 2015

Cerecor Bolsters Clinical Pipeline with Acquisition of Phase 2-ready Kappa Opioid Receptor Antagonist from Eli Lilly and Company

Read More